The efficacy and role of Valganciclovir: treatment principles and clinical effects

Valganciclovir is an antiviral drug widely used to prevent and treat infections caused by cytomegalovirus (CMV), especially in immunocompromised people, such as organ transplant recipients or HIV/AIDS patients. The drug is a prodrug of Ganciclovir. It is rapidly converted into the active form in the body after oral administration, providing antiviral activity comparable to intravenous ganciclovir, thus significantly improving patients' medication compliance.

The mechanism of action of valganciclovir is by inhibiting the activity of viralDNA polymerase, thereby interfering with the replication process of viral DNA. It is hydrolyzed into ganciclovir by liver esterase in the body, and further phosphorylated into ganciclovir triphosphate, which competes with viral DNA to be inserted into the viral genome, thereby blocking the extension of the viral replication chain and ultimately achieving viral suppression. Especially for the CMV virus, this mechanism is highly specific and effective, and is an indispensable antiviral weapon in current clinical treatment.

In terms of clinical application, valganciclovir is most commonly used to prevent CMV infection in high-risk groups such as kidney transplants, heart transplants, or liver transplants. Studies have shown that it can significantly reduce CMV infection rates and viremia during postoperative preventive treatment, and improve long-term graft survival rates. In terms of treatment, it is often used for the initial induction treatment and maintenance treatment of CMV retinitis, especially in HIV-infected patients. It has been proven to significantly delay the progression of retinopathy and even maintain visual function. In addition, there is also potential off-label use for other diseases caused by human herpes viruses (such as Epstein-Barr virus or HHV-6), although its efficacy and safety still need to be confirmed by further studies.

In terms of efficacy, multiple multi-center clinical trials have confirmed the non-inferiority or even superiority of valganciclovir inCMV prevention and treatment. For example, a study on organ transplant patients showed that oral valganciclovir was as effective as intravenous ganciclovir in preventing CMV infection, but patients had higher compliance, good gastrointestinal tolerance, and significant improvement in quality of life. Another study found in AIDS-related CMV retinitis that after 8 weeks of initial treatment, viral replication was significantly suppressed in more than 90% of patients, and retinal lesions were stabilized or improved.

However, it needs to be emphasized that this drug also has a high risk of toxicity, especially its obvious suppressive effect on bone marrow, including neutropenia, anemia, and thrombocytopenia. Complete blood counts must therefore be monitored closely during treatment, especially in patients receiving concomitant immunosuppressants. For patients with renal insufficiency, the risk of metabolite accumulation is increased, which needs to be determined according to the glomerular filtration rate (GFR) adjust dosage to prevent drug accumulation leading to toxicity. In addition, valganciclovir is teratogenic to the fetus. Women should avoid pregnancy while taking the drug, and men should also pay attention to taking effective contraceptive measures during the drug and for at least 90 days after stopping the drug.

In terms of drug resistance, long-term or repeated use of valganciclovir may cause the virusDNA polymerase gene to mutate, resulting in drug-resistant strains and reduced drug efficacy. This is particularly common in patients who have received long-term antiviral prophylaxis after organ transplantation. Clinicians need to be alert to early signs of treatment failure, such as increased viral load and relapse of symptoms. If necessary, alternative drugs such as foscarnet or higher-level antiviral strategies can be used.

Reference materials:https://go.drugbank.com/drugs/DB01610